FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Spink Katharine E. 		2. Issuer Name and Ticker or Trading Symbol

Asterias Biotherapeutics, Inc. [ AST ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
EVP & COO
(Last)          (First)          (Middle)

6300 DUMBARTON CIRCLE 		3. Date of Earliest Transaction (MM/DD/YYYY)

6/5/2017
(Street)

FREMONT, CA 94555
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   6/5/2017     F (1)    7260   D $3.2   10949   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option   $2.34                    8/1/2013   3/9/2020   Common Stock   192500     192500   (2) D    
Stock Option   $3.9                    2/12/2016   2/12/2025   Common Stock   100000     100000   (3) D    
Stock Option   $5.45                    12/31/2015   11/4/2025   Common Stock   100000     100000   (4) D    
Stock Option   $3.64                    2/26/2017   2/26/2026   Common Stock   165000     165000   (5) D    
Stock Options   $3.45                    3/30/2018   3/30/2027   Common Stock   150000     150000   (6) D    

Explanation of Responses:
(1)  In accordance with Rule 16b-3, represents shares withheld by the Issuer to satisfy tax withholding obligation upon vesting of a previously reported restricted stock award.
(2)  Of such stock options, 4,167 have vested not as of the date hereof.
(3)  Of such stock options, 43,751 have vested not as of the date hereof.
(4)  Of such stock options, 62,500 have vested not as of the date hereof.
(5)  Of such stock options, 113,438 have not vested as of the date hereof.
(6)  Of such stock options, 150,000 have not vested as of the date hereof.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Spink Katharine E.
6300 DUMBARTON CIRCLE
FREMONT, CA 94555

EVP & COO

Signatures
/s/ Katharine E. Spink 6/7/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Asterias Biotherapeutics, Inc. (AMEX:AST)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Asterias Biotherapeutics, Inc. Charts.
Asterias Biotherapeutics, Inc. (AMEX:AST)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Asterias Biotherapeutics, Inc. Charts.